These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33576119)

  • 1. The tumor immune contexture of salivary duct carcinoma.
    Schvartsman G; Bell D; Rubin ML; Tetzlaff M; Hanna E; Lee JJ; Weber R; Phan J; Glisson BS; Ferrarotto R
    Head Neck; 2021 Apr; 43(4):1213-1219. PubMed ID: 33576119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
    Yang RK; Zhao P; Lu C; Luo J; Hu R
    Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center.
    Mayer M; Wolber P; Prinz J; Jansen L; Esser J; Shabli S; Quaas A; Klußmann JP; Sharma SJ; Nachtsheim L; Arolt C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3779-3789. PubMed ID: 38587651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM; Chiosea SI
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
    Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities.
    Alame M; Cornillot E; Cacheux V; Tosato G; Four M; De Oliveira L; Gofflot S; Delvenne P; Turtoi E; Cabello-Aguilar S; Nishiyama M; Turtoi A; Costes-Martineau V; Colinge J
    Theranostics; 2020; 10(10):4383-4394. PubMed ID: 32292502
    [No Abstract]   [Full Text] [Related]  

  • 9. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
    Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
    Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
    Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
    Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
    Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
    Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma.
    van Boxtel W; Uijen MJM; Verhaegh GW; Willems SM; Jonker MA; ; Schalken JA; van Engen-van Grunsven ICH; van Herpen CML
    Oral Oncol; 2020 Nov; 110():105018. PubMed ID: 33039794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.
    Jalaly JB; Sanati S; Chernock RD; Dibe DG; El-Mofty SK
    Head Neck Pathol; 2018 Dec; 12(4):488-492. PubMed ID: 29302899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
    Kusafuka K; Kawasaki T; Maeda M; Yamanegi K; Baba S; Ito Y; Inagaki H; Nakajima T
    Histopathology; 2017 Jan; 70(2):164-173. PubMed ID: 27079821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
    Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
    Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.
    Mitani Y; Lin SH; Pytynia KB; Ferrarotto R; El-Naggar AK
    Clin Cancer Res; 2020 Mar; 26(5):1175-1184. PubMed ID: 31772120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
    Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
    Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.